Profile: Amneal Pharmaceuticals Inc (AMRX.N)
20 Sep 2019
Amneal Pharmaceuticals, Inc., incorporated on October 4, 2017, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company’s pipeline generics portfolios cover a range of dosage forms and delivery systems, including oral solids, such as tablets, capsules and powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topical. The Company operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. It has a range of dosage capability across oral solids, solutions, suspensions, creams, gels, ointments, nasal sprays, hormonals, patches, oral thin films, dry powder inhalers, metered dose inhalers, cytotoxics, injectables, ophthalmics, otics, and tablets / capsules.
The Company is focused on developing, manufacturing, selling and distributing solid dose and alternative dosage form products covering a range of therapeutic areas and drug-delivery mechanisms or product development formulations. It also develops, manufactures, sells and distributes specialty generic pharmaceuticals. It sells and distributes generic pharmaceutical products through over four sales channels, such as the Generics sales channel, which includes generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains, and others; Rx Partner sales channel, which includes generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; Private Label sales channel, which includes generic pharmaceutical over-the-counter (OTC) and prescription products it sells to unrelated third parties and in-turn sells the product under their own label, and OTC Partner sales channel, which includes sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical companies pursuant to alliance, collaboration and supply agreements.
The Company's Specialty Pharma segment is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of central nervous system (CNS) disorders, which include migraine, multiple sclerosis and post-herpetic neuralgia. The Company's branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Specialty Pharma segment is also engaged in the sale and distribution of four other branded products, including Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches, and Emverm (mebendazole) 100 milligram chewable tablets, indicated for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infection.
The Company competes with Teva Pharmaceutical Industries Ltd., Mylan N.V., Fresenius Medical Care AG & Co. KGAA /Akorn, Inc., Sun Pharmaceutical Industries Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Endo International plc and Sandoz.
Amneal Pharmaceuticals Inc
400 Crossing Blvd Fl 3
BRIDGEWATER NJ 08807-2863